NasdaqCM - Nasdaq Real Time Price USD

X4 Pharmaceuticals, Inc. (XFOR)

Compare
0.1963
-0.0137
(-6.52%)
As of 10:41:42 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,557
2,557
--
--
--
Cost of Revenue
797
797
--
--
--
Gross Profit
1,760
1,760
--
--
--
Operating Expense
143,161
143,161
107,522
88,078
75,349
Operating Income
-141,401
-141,401
-107,522
-88,078
-75,349
Net Non Operating Interest Income Expense
-2,999
-2,999
-1,195
-3,774
-3,632
Other Income Expense
107,260
107,260
7,628
-1,987
-9,698
Pretax Income
-37,140
-37,140
-101,089
-93,839
-88,679
Tax Provision
310
310
78
28
17
Net Income Common Stockholders
-37,450
-37,450
-101,167
-96,413
-102,639
Diluted NI Available to Com Stockholders
-37,450
-37,450
-101,167
-96,413
-102,639
Basic EPS
-0.19
-0.19
-0.57
-1.52
-3.99
Diluted EPS
-0.19
-0.19
-0.57
-1.52
-3.99
Basic Average Shares
201,062.2110
201,062.2110
177,812.4800
63,526
25,749
Diluted Average Shares
201,062.2110
201,062.2110
177,812.4800
63,526
25,749
Total Operating Income as Reported
-36,401
-36,401
-107,522
-87,569
-85,107
Total Expenses
143,958
143,958
107,522
88,078
75,349
Net Income from Continuing & Discontinued Operation
-37,450
-37,450
-101,167
-93,867
-88,696
Normalized Income
-121,923.1200
-121,923.1200
-106,755.4600
-95,612.9000
-81,305.4800
Interest Income
5,769
5,769
4,582
219
10
Interest Expense
8,768
8,768
5,777
3,993
3,642
Net Interest Income
-2,999
-2,999
-1,195
-3,774
-3,632
EBIT
-28,372
-28,372
-95,312
-89,846
-85,037
EBITDA
-27,576
-27,576
-94,893
-89,333
-84,538
Reconciled Cost of Revenue
797
797
--
--
--
Reconciled Depreciation
796
796
419
513
499
Net Income from Continuing Operation Net Minority Interest
-37,450
-37,450
-101,167
-93,867
-88,696
Total Unusual Items Excluding Goodwill
106,928
106,928
7,074
2,210
-10,124
Total Unusual Items
106,928
106,928
7,074
2,210
-10,124
Normalized EBITDA
-134,504
-134,504
-101,967
-91,543
-74,414
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
22,454.8800
22,454.8800
1,485.5400
464.1000
-2,733.4800
12/31/2021 - 11/16/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PDSB PDS Biotechnology Corporation
0.9401
-10.41%
 
DAWN Day One Biopharmaceuticals, Inc.
7.29
-5.51%
 
MREO Mereo BioPharma Group plc
2.0350
-7.92%
 
MCRB Seres Therapeutics, Inc.
0.6723
-2.23%
 
INAB IN8bio, Inc.
0.1494
-7.32%
 
XLO Xilio Therapeutics, Inc.
0.6851
-2.16%
 
EYEN Eyenovia, Inc.
0.9860
-11.17%
 
ARDX Ardelyx, Inc.
4.5550
-3.90%
 
CLRB Cellectar Biosciences, Inc.
0.2695
-8.08%
 
CGTX Cognition Therapeutics, Inc.
0.3421
-11.37%